ProXN has made a notable impression in the UKI, earning a peer-nomination for a Safety in Beauty Award for Best Topical Skincare within its first year. This prestigious recognition underscores proXN's commitment to efficacy, innovation, and safety in skin health treatments.
Renowned for pioneering the use of Xanthohumol, the most potent antioxidant ever discovered, as a primary active ingredient, proXN has quickly earned the trust of both consumers and industry professionals. This nomination is a testament to proXN's rapid impact and promising future in the competitive skin health landscape. Xanthohumol (XN) demonstrates exceptional efficacy in addressing inflam-aging through its biological effects:
- XN inhibits NF-kB, a regulator of immune response and inflammation.
- XN modulates GMCF, crucial for melanogenesis process and inflammation regulation.
- XN reduces IL-12, a cytokine associated with inflammatory skin conditions like acne rosacea and atopic dermatitis.
Geraldine Shaker-Kekati, Business Manager UKI, says, ‘It's been an incredible journey in a very short time. Entering the UKI market in the first year is a significant challenge due to the established competition. Being recognised through peer nominations is an immensely rewarding achievement. The case studies coming out of the UKI speak for themselves, and the feedback from our practitioners is clear—it works.’
XN (Xanthohumol) is a molecule found in hops, that was discovered over 100 years ago. It has been widely studied by the medical community for more than four decades, for its potent antioxidant and anti-inflammatory properties. There are currently over 800 clinical studies on PubMed.
ProXN discovered the synthesis pathway to make XN bioavailable in 2018. However, like Vitamin C, XN is unstable in its original form. The founders, Paulina Stopczk and Aneta Czaplicka then collaborated with leading scientists in Poland for another year to encapsulate it into a highly stabilised form. This advanced formulation boasts potency 30 times greater than Vitamin C and 200 times greater than resveratrol, with this exceptional potency being exclusive to proXN.
Join us at the 10th National Aesthetic Nursing Conference for an insightful panel discussion on inflam-aging—accelerated aging associated with chronic inflammation on November 24th.
Case study: patient one
Condition
- Acne rosacea
Symptoms
- First appeared in December 2023
Medical history
- January 2024: GP prescribed Lymecycline for two weeks. Symptoms subsided during the course of antibiotics but reappeared immediately after completing the lymecycline.
- Subsequent prescription: GP prescribed a second round of Lymecycline for two months.
ProXN professional treatments
- Number of treatments: 5
Case study duration
- A total of 10 weeks. Commencing April 24 2025, ending July 3 2024.
Homecare support protocol:
- Recovery Cleansing Oil
- Prime Mist
- Antioxidant Therapy
- Antioxidant Therapy Light
- LF Master